Company news
Inflarx N.v. (NASDAQ:IFRX) news
Inflarx N.v. news releases on 6ix. Latest, May 21, 2021: Tony Gibney Joins InflaRx Board of Directors
Press releases — page 3
Tony Gibney Joins InflaRx Board of Directors
May 20, 2021
InflaRx Reports First Quarter 2021 Financial & Operating Results
May 11, 2021
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
May 10, 2021
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum
April 14, 2021
InflaRx Reports Full Year 2020 Financial & Operating Results
March 24, 2021
InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
February 28, 2021
InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
February 24, 2021
InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
February 23, 2021
InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
February 10, 2021
InflaRx Provides Update on Vilobelimab (IFX-1) Development
January 10, 2021
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
January 4, 2021
InflaRx Reports Q3 2020 Financial & Operating Results
October 28, 2020
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
September 16, 2020
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
September 13, 2020
InflaRx Reports Q2 2020 Financial & Operating Results
July 29, 2020
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
July 20, 2020